Drugs /

multi-epitope folate receptor alpha peptide vaccine

Back to Drugs List

Overview

NCI Definition [1]:
A peptide vaccine containing five immunogenic peptide epitopes of the human folate receptor alpha (FR alpha or FOLR1), including FR30, FR56, FR76, FR113, and FR238, with potential immunomodulating and antineoplastic activity. Upon administration, the multi-epitope FR alpha peptide vaccine may induce a cytotoxic T-lymphocyte (CTL) response against FR alpha-overexpressing tumor cells. FR alpha is a high-affinity folate-binding protein and a member of the folate receptor family; this receptor is overexpressed in a majority of ovarian cancers and in about 50% of breast cancers.

Clinical Trials

View Clinical Trials for multi-epitope folate receptor alpha peptide vaccine

Multi-epitope folate receptor alpha peptide vaccine has been investigated in 2 clinical trials, of which 1 is open and 1 is closed. Of the trials investigating multi-epitope folate receptor alpha peptide vaccine, 2 are phase 2 (1 open).

ER Negative, ER No Expression, and HER2 Deficient Expression are the most frequent biomarker inclusion criteria for multi-epitope folate receptor alpha peptide vaccine clinical trials.

Breast carcinoma is the most common disease being investigated in multi-epitope folate receptor alpha peptide vaccine clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Multi-Epitope Folate Receptor Alpha Peptide Vaccine
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Multi-Epitope Folate Receptor Alpha Peptide Vaccine
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating multi-epitope folate receptor alpha peptide vaccine and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
frα peptide vaccine, fr alpha peptide vaccine, hufr-1, fr alpha peptide vaccine
NCIT ID [1]:
C101777

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.